NASDAQ · RAIN
Rain Enhancement Technologies Holdco, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for RAIN: Nov 12, 2026
Rain Enhancement Technologies Holdco, Inc. Class A Common Stock is estimated to report earnings on 11/12/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. The reported EPS for the same quarter last year was $-0.29.
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Quiver Quantitative · Fintel · The Motley Fool · TipRanks- Quiver Quantitative · Feb 10, 5:02 PM ESTInsider Purchase: 10% owner at $RAIN Buys 13,173 SharesPAUL T DACIER, a 10% owner of $RAIN, bought 13,173 shares of the company on 02-06-2025 for an estimated $150,040. This trade was reported by Quiver Quantitative using data from a recent SEC filing. This increased their holdings of this class of stock by approximately inf%. Follow
- Quiver Quantitative · Dec 31, 8:00 PM ESTInsider Purchase: 10% owner at $RAIN (RAIN) Buys 8,782 SharesPAUL T DACIER, a 10% owner of $RAIN ($RAIN), bought 8,782 shares of the company on 12-31-2024. This trade was reported by Quiver Quantitative using data from a recent SEC filing. This increased their holdings by approximately 0.5%. Following this trade, they now own 1,848,104 sha
- Fintel · Sep 18, 10:12 AM EDTCitigroup Maintains Rain Oncology (RAIN) Neutral RecommendationFintel reports that on September 18, 2023, Citigroup maintained coverage of Rain Oncology (NASDAQ:RAIN) with a Neutral recommendation.
- Fintel · Jun 2, 6:43 PM EDTHC Wainwright & Co. Reiterates Rain Oncology (RAIN) Neutral RecommendationFintel reports that on June 2, 2023, HC Wainwright & Co. reiterated coverage of Rain Oncology (NASDAQ:RAIN) with a Neutral recommendation.
- Fintel · May 30, 6:25 PM EDTEF Hutton Maintains Rain Oncology (RAIN) Hold RecommendationFintel reports that on May 30, 2023, EF Hutton maintained coverage of Rain Oncology (NASDAQ:RAIN) with a Hold recommendation.
- Fintel · May 22, 8:25 PM EDTUnusual Put Option Trade in Rain Oncology (RAIN) Worth $310.04KOn May 22, 2023 at 11:22:07 ET an unusually large $310.04K block of Put contracts in Rain Oncology (RAIN) was sold, with a strike price of $7.50 / share, expiring in 116 day(s) (on September 15, 2023). Fintel tracks all large options trades, and the premium spe
- The Motley Fool · May 22, 3:15 PM EDTWhy Shares of Rain Oncology Are Plummeting TodayWhat happened Shares of Rain Oncology (NASDAQ: RAIN) were down 87% Monday afternoon after the precision oncology company released top-line results for its lead therapy, milademetan, to treat dedifferentiated liposarcoma, a type of cancer affecting fatty tissue, usually in the arm
- Fintel · May 12, 2:45 PM EDTEF Hutton Reiterates Rain Oncology (RAIN) Buy RecommendationFintel reports that on May 12, 2023, EF Hutton reiterated coverage of Rain Oncology (NASDAQ:RAIN) with a Buy recommendation.
- Fintel · May 1, 8:44 PM EDTUnusual Put Option Trade in Rain Oncology (RAIN) Worth $182.28KOn May 1, 2023 at 12:40:52 ET an unusually large $182.28K block of Put contracts in Rain Oncology (RAIN) was bought, with a strike price of $7.50 / share, expiring in 46 day(s) (on June 16, 2023). Fintel tracks all large options trades, and the premium spent on
- Fintel · May 1, 8:43 PM EDTUnusual Put Option Trade in Rain Oncology (RAIN) Worth $361.08KOn May 1, 2023 at 12:40:52 ET an unusually large $361.08K block of Put contracts in Rain Oncology (RAIN) was bought, with a strike price of $7.50 / share, expiring in 46 day(s) (on June 16, 2023). Fintel tracks all large options trades, and the premium spent on
- Fintel · Mar 22, 12:14 AM EDTSVB Leerink Initiates Coverage of Rain Therapeutics (RAIN) with Outperform RecommendationOn March 21, 2023, SVB Leerink initiated coverage of Rain Therapeutics with a Outperform recommendation.
- TipRanks · Feb 19, 10:53 AM ESTTipRanks ‘Perfect 10’ List: There’s an Opportunity Brewing in These 2 Stocks
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Rain Enhancement Technologies Holdco, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.